Related Experiment Video
Updated: Mar 11, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
Published on: November 27, 2019
Pediatric acute liver failure of undetermined cause: A research workshop
Estella M Alonso1, Simon P Horslen2, Edward M Behrens3
1Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
Insights
Pediatric acute liver failure (PALF) with unknown causes is linked to hyperinflammation, similar to HLH/MAS. Impaired T-cell function and suppressed progenitor cells hinder liver regeneration and recovery in children.
Area of Science:
- Hepatology
- Immunology
- Pediatric Critical Care
Background:
- Pediatric acute liver failure (PALF) is a severe condition in children with a significant percentage lacking a clear diagnosis.
- Undetermined PALF cases exhibit poorer outcomes, including lower survival and higher transplant/death rates.
- The clinical presentation of indeterminate PALF resembles hyperinflammatory conditions like hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
Purpose of the Study:
- To integrate research findings on indeterminate PALF.
- To establish a foundation for new mechanistic studies and future treatment trials.
- To explore the role of inflammation and cellular dysfunction in PALF pathogenesis.
Main Methods:
- Workshop convening clinicians and basic scientists.
- Review of clinical phenotypes and inflammatory markers.
- Discussion of cellular mechanisms in hepatic regeneration.
Main Results:
- Indeterminate PALF shares features with HLH and MAS, suggesting a hyperinflammatory component.
- Failure of cytotoxic T cells may impair inflammatory control, leading to liver injury.
- Bone marrow-derived sinusoidal endothelial cell progenitor cells (sprocs) are crucial for hepatic regeneration but may be suppressed by inflammation.
Conclusions:
- Insights from HLH/MAS trials may guide PALF therapeutic strategies.
- Reducing systemic inflammation and neuroinflammation is key to improving survival.
- Multicenter collaboration and biorepository management are essential for rare disease research.
Abstract:
Pediatric acute liver failure (PALF) is a potentially devastating condition that occurs in previously healthy children of all ages and frequently leads to a rapid clinical deterioration. An identified cause for liver injury is lacking in approximately 30% of cases. Children with undetermined diagnosis have lower spontaneous survival and higher rates of transplantation and death than other diagnostic groups. A single-day workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases brought together clinicians and basic scientists to integrate aligned research findings and develop a foundation for new mechanistic studies and future treatment trials. The clinical phenotype of indeterminate PALF shares important similarities to the hyperinflammatory state characteristic of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS). A failure of cytotoxic T cells to limit or contract inflammatory responses may propagate injury and lead to a local and systemic milieu that does not support normal hepatic regeneration. Evidence was presented that bone marrow (BM)-derived Sinusoidal endothelial cell PROgenitor Cells (sprocs) play a vital role in hepatic regeneration. Overwhelming systemic inflammatory responses may suppress mobilization of BM sprocs and dampen hepatic recovery.
Conclusion:
Experience gained through treatment trials of HLH and MAS in childhood may inform study design for therapy of PALF. Successful approaches to limiting neuroinflammation through reduction of systemic inflammation and standardized neuroprotection protocols that limit glial injury could significantly improve intact survival. Finally, given that PALF is a rare disease, investigative efforts must include broad multicenter collaboration and careful stewardship of biorepository specimens. (Hepatology 2017;65:1026-1037).
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Acute Kidney Injury I: Introduction
Pharmacokinetics in Pediatric Patients: Drug Distribution

